Related Experiment Videos

Rapamycin and wortmannin enhance replication of a defective encephalomyocarditis virus

Y V Svitkin1, H Hahn, A C Gingras

  • 1Department of Biochemistry and McGill Cancer Center, McGill University, Montreal, Quebec, Canada H3G 1Y6.

Journal of Virology
|June 17, 1998
PubMed

Insights

Inhibiting the PI3 kinase-FRAP pathway with rapamycin or wortmannin aids Encephalomyocarditis virus (EMCV) replication. This pathway inhibition partially rescues EMCV strains with defective 2A proteins, reversing slow-virus phenotypes.

Area of Science:

  • Virology
  • Molecular Biology
  • Cellular Signaling

Background:

  • The phosphatidylinositol 3-kinase (PI3 kinase)-FRAP pathway regulates protein synthesis.
  • Inhibitors like rapamycin activate 4E-BP1, a key translation repressor.
  • Encephalomyocarditis virus (EMCV) infection triggers host translation shutoff via 4E-BP1 activation.

Purpose of the Study:

  • To investigate the role of the PI3 kinase-FRAP pathway in EMCV infection.
  • To examine the effect of pathway inhibition on EMCV strains with mutations in the 2A coding region.
  • To determine if PI3 kinase-FRAP inhibition can rescue viral replication defects.

Main Methods:

  • Generated two defective EMCV strains by deleting portions of the 2A coding region.
  • Infected BHK-21 cells with wild-type and mutant EMCV strains.
  • Treated infected cells with PI3 kinase-FRAP inhibitors (rapamycin, wortmannin) and assessed viral protein synthesis and host translation.

Main Results:

  • Deletions in the EMCV 2A region impaired viral protein synthesis and abolished host translation shutoff.
  • Treatment with rapamycin and wortmannin significantly increased translation and yield of mutant viruses.
  • PI3 kinase-FRAP pathway inhibition partially complemented the 2A mutations, reversing a slow-virus phenotype.

Conclusions:

  • The PI3 kinase-FRAP signaling pathway plays a significant role in EMCV replication and host translation control.
  • Inhibition of this pathway can partially rescue the replication defects of EMCV strains with mutations in the 2A protein.
  • Targeting the PI3 kinase-FRAP pathway offers a potential strategy to modulate EMCV infection outcomes.

Related Concept Videos